ArticleBritish journal of cancer2004
Kallikrein gene downregulation in breast cancer.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- The utility of breastmilk for genetic or genomic studies: a systematic review.Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine · 2013Pooled it
- ADAMTS-8 and kallikrein-related peptidases 10 and 5 proteases also have a tumor suppression role.World journal of clinical oncology · 2025Review
- Article
- Kallikrein-Related Peptidase 12 (KLK12) in Breast Cancer as a Favorable Prognostic Marker.International journal of molecular sciences · 2023Article
- A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA Expression.Life (Basel, Switzerland) · 2022Article
- Effects of iron modulation on mesenchymal stem cell-induced drug resistance in estrogen receptor-positive breast cancer.Oncogene · 2022Article
- MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10.Histology and histopathology · 2022Article
- Localized and Systemic Inflammatory Mediators in a Murine Acute Mastitis Model.Journal of inflammation research · 2021Article
- Novel Biomarkers Aim at Detecting Metastatic Sentinel Lymph Nodes in Breast CancerIranian biomedical journal · 2020Article
- Circulating cell-free DNA release in vitro: kinetics, size profiling, and cancer-related gene methylation.Journal of cellular physiology · 2019Article
- Article
- Expression and clinical significance of KLK5-8 in endometrial cancer.American journal of translational research · 2019Article
- Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.Clinical and experimental medicine · 2018Article
- Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.Oncotarget · 2018Article
- Elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a better prognosis in advanced high-grade serous ovarian cancer patients.American journal of cancer research · 2018Article
- Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.PloS one · 2017Article
- KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes.Molecular oncology · 2016Article
- Kallikreins - The melting pot of activity and function.Biochimie · 2016Review
- Expression of Human Kallikreins 4, 8, 10, 11 and 13 in Pleomorphic Adenomas and Mucoepidermoid Carcinomas.Iranian journal of pathology · 2016Article
- NES1/KLK10 gene represses proliferation, enhances apoptosis and down-regulates glucose metabolism of PC3 prostate cancer cells.Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent evidence suggests that many members of the human kallikrein gene family are differentially regulated in breast cancer and other endocrine-related malignancies. In this study, we utilised the serial analysis of gene expression (SAGE) and expressed sequence tag (EST) databases of the Cancer Genome Anatomy Project (CGAP) to perform in silico analyses of the expression pattern of the 15 human kallikrein genes in normal and cancerous breast tissues and cell lines using different analytical tools such as Virtual Northern blotting, Digital Differential Display and X-profiler. Our results indicate that at least four kallikrein genes (KLK5, 6, 8, 10) are downregulated in breast cancer. Probing eight normal and 24 breast cancer SAGE libraries with gene-specific tags for each of the above kallikreins indicated moderate-to-high expression densities in normal breast (27-319 tags per million; tpm, in two to five out of eight libraries), compared to no or low expression (0 - 34 tpm in zero to two libraries out of 24) in breast cancer. These data were verified by screening the EST databases, where all mRNA clones isolated for these genes, except for one in each, were from normal breast libraries, with no clones detected from breast cancer tissues or cell lines (with the exception of KLK8). X-profiler comparison of two pools of normal and breast cancer libraries further verified the presence of significant downregulation of expression levels of 4 of the kallikreins genes (KLK5, 6, 10, 12). We experimentally verified the downregulation of these four kallikreins (KLK5, 6, 8, 10 and 12) by RT - PCR analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.